July 2024

Antibody Discovery Processes

2024-12-03T13:51:44-05:00July 3rd, 2024|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Updated: July 7, 2024 Contents Introduction Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection and Downstream Characterization Introduction [...]

May 2024

January 2024

October 2023

New Antibody Characterization Essentials from Discovery to Clinic

2024-04-24T10:34:49-04:00October 4th, 2023|Webinars|

In this webinar, you will learn: Workflows for antibody characterization that extend beyond the primary amino acid sequence How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts How to ensure high-quality antibody production with [...]

May 2023

Functional Characterization of Therapeutic Antibodies

2024-12-03T13:57:00-05:00May 3rd, 2023|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: April 24, 2023 Contents Introduction Functions of Therapeutic Antibodies Functional Assays for Therapeutic Antibodies Functional Characterization in the Therapeutic Antibody Discovery Process Introduction Monoclonal antibodies (mAbs) and related biological products often present as ideal therapeutics largely due to: Their [...]

Secure Full Antibody and Target IP Protection with Next Generation Protein Sequencing

2024-04-01T15:46:27-04:00May 3rd, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: April 21, 2023 Contents Introduction Target Specification for First Generation Antibodies Patent Strategies for Second-Generation Antibodies Next Generation Protein Sequencing and Proteomics Strengthens IP Protections Introduction Intellectual property (IP) protection is a critical step during the commercialization of antibodies [...]

April 2023

Immunochemical Characterization of Therapeutic Antibodies

2024-05-06T15:49:12-04:00April 17th, 2023|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: April 14, 2023 Contents Introduction Immunochemical Properties of Therapeutic Antibodies Rapid Immunochemical Characterization of Antibodies Introduction Therapeutic antibodies, predominantly monoclonal antibodies (mAbs), are a rapidly expanding class of drugs with over 100 mAb-based biologics now approved for the treatment [...]

Navigating Intellectual Property Protection for Antibodies

2024-05-06T15:50:21-04:00April 1st, 2023|Webinars|

In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of De Novo Protein Sequencing, SPR assays, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based assets, [...]

February 2023

Nanobody Lead Optimization with Epitope Mapping and Binning

2024-12-03T12:46:01-05:00February 14th, 2023|Webinars|

In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]

January 2023

Antibody Affinity and Avidity – The Strength of a Single Interaction Versus a Multivalent Interaction

2024-05-06T15:51:53-04:00January 9th, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: January 6, 2023 Contents Introduction What is Affinity? What is Avidity? Measuring Affinity and Avidity: ELISA or SPR? Measuring Affinity And Avidity For Biological Applications Affinity and Avidity Analysis via SPR with Rapid Novor Introduction Kinetics of antibody-antigen interactions [...]

December 2022

The Hunt for Novel Therapeutics Through Antibody Engineering

2023-06-21T10:25:09-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]

Cell Specific Protein Degradation with Antibody Conjugated PROTACs

2023-05-25T10:29:24-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]

October 2022

Characterizing Biomolecular Interactions with Surface Plasmon Resonance

2024-12-02T16:46:34-05:00October 21st, 2022|Articles|

Biological processes are driven by molecules that interact through specific molecular contacts, often to form a stable complex. These interactions are typically defined by the principles of thermodynamics as well as biomolecular structure and recognition. At the simplest level is the interaction between a target molecule with a specific binding site and a probing molecule that binds to that site, resulting in the bound complex.

September 2022

Antibody-Drug Conjugates as Anti-Cancer Therapeutics

2024-01-22T13:13:13-05:00September 19th, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]

August 2022

Surface Plasmon Resonance Spectroscopy

2024-05-06T15:55:26-04:00August 16th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Updated: January 19, 2023 (Published: August 11, 2022) Contents What is Surface Plasmon Resonance Spectroscopy? What is SPR Used For? How Does SPR Work? SPR Experimental Workflow SPR Sensorgram SPR Advantages SPR Applications SPR Antibody-Antigen Interaction Analysis at Rapid Novor What is [...]

Moving Towards Biosimilar Drugs

2024-06-13T16:50:51-04:00August 4th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: August 3, 2022 Contents What are Biosimilar Drugs? Why are Biosimilars Being Developed? Biosimilars are not the Equivalent of Generics Biosimilar Development Biosimilar Monoclonal Antibodies De Novo Protein Sequencing Solutions in Biosimilar Development What are Biosimilar Drugs? Biosimilar drugs, [...]

July 2022

Adeno-Associated Virus Vectors for Gene Therapy Delivery

2024-12-03T10:41:17-05:00July 14th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]

June 2022

Chimeric Antigen Receptors and T cells – CAR-T

2024-12-03T10:43:11-05:00June 21st, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]

February 2022

Camelid Antibodies and Nanobodies

2024-12-03T10:58:32-05:00February 4th, 2022|Articles|

Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]

September 2021

Monoclonal vs Polyclonal Antibody Drugs

2024-12-03T11:21:15-05:00September 8th, 2021|Articles|

The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.